Skip to main content
Caplight Logo









Valo Therapeutics

Valo Therapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://www.valotx.com/

Last Round

VC Round

Mar 10, 2025

Total Funding Raised

$24.37M

Company Overview

Valo Therapeutics is a biotechnology company that develops novel immunotherapies for cancer and infectious diseases using its proprietary PeptiCRAd platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyoncolytic viruscancer immunotherapycheckpoint inhibitorsviral vectorsbiotech R&Ddrug discoveryprecision medicineclinical trialscold to hot tumorscancer vaccineonco-immunologypeptide-based therapytumor microenvironment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Valo Therapeutics Comparables

Compare Valo Therapeutics with similar companies based on industry and business-model similarity.

Valo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TILT Biotherapeutics
89%
Nouscom
83%
Accession Therapeutics Limited
82%

Valo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 10, 2025
GrantFeb 14, 2023
Private EquityNov 15, 2021
SeedFeb 6, 2020
DebtJul 4, 2017
Seed
Jan 1, 2017

Key People

Founding team and executive leadership

Marcella Origgi

CEO Of ValoTX OY and of Valo SRL

Executive Team

Sari Pesonen

Chief Scientific Officer, Chief Executive Officer

Executive Team

Harri Järveläinen

Chief Operating Officer

Executive Team

Valo Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 34% MoM, from 674 to 900.

  • Apr 9, 2025

    Marcella Origgi joins as the new CEO, coming from Johnson & Johnson Innovation.

Valo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Valo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Valo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range11
Year Founded2016
Last FundingMar 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?